Article Text

Download PDFPDF
LKM antibody: getting in some target practice
  1. Institute of Hepatology
  2. University College London Medical School
  3. 69–75 Chenies Mews
  4. London WC1E 6HX, UK
  5. Email:

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    See article on page 553

    In the current issue of the journal (see page 553), Muratoriet al provide convincing evidence that cytochrome P4502D6 (CYP2D6) is present on the liver cell plasma membrane. This finding has important implications because CYP2D6 is the main target of liver kidney microsomal antibody type 1 (LKM1). Not only is LKM1 the serological hallmark of autoimmune hepatitis type 2 but it is also found in up to 10% of patients with chronic hepatitis C virus (HCV) infection where it appears to single out patients experiencing serious side effects while receiving interferon treatment.1

    The issue as to whether CYP2D6 is present on the plasma membrane was critically reviewed in 19932 but was not resolved in view of the contrasting evidence at the time. Muratoriet al have settled this matter by incubating LKM1 containing sera with live hepatocytes …

    View Full Text

    Linked Articles